Publications by authors named "Eva L Hanze"
Clin Pharmacol Ther
June 2018
Article Synopsis
- GDC-0853 is a selective and reversible small molecule inhibitor of Bruton's tyrosine kinase (BTK), showing promising safety in Phase I trials with no serious adverse events.
- In studies, it was well tolerated, with the maximum dose not reached during testing up to 600 mg for single doses and 500 mg for multiple doses.
- Pharmacokinetic data indicates that a once-daily dose could effectively maintain BTK inhibition, suggesting potential for treating autoimmune conditions such as rheumatoid arthritis and lupus.
